Do nonglycaemic effects such as weight loss account for HbA1c lowering with efpeglenatide?: Insights from the AMPLITUDE-O trial Article Early Access

International Collaboration

cited authors

  • Gerstein, Hertzel C.; Yang, Mu; Lee, Shun Fu; Branch, Kelley R. H.; Del Prato, Stefano; Lam, Carolyn S. P.; Lopes, Renato D.; Pratley, Richard; Rosenstock, Julio; Sattar, Naveed

Publication Date

  • September 16, 2024

webpage

published in

category

keywords

  • GLP-1 RA
  • HbA1c
  • efpeglenatide
  • mediation